Journal article
Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016
British journal of haematology, Vol.188(3), pp.383-393
08/07/2019
DOI: 10.1111/bjh.16124
PMCID: PMC7003731
PMID: 31392724
Abstract
Limited data are available regarding contemporary multiple myeloma (MM) treatment practices in Latin America. In this retrospective cohort study, medical records were reviewed for a multinational cohort of 1103 Latin American MM patients (median age, 61 years) diagnosed in 2008–2015 who initiated first‐line therapy (LOT1). Of these patients, 33·9% underwent autologous stem cell transplantation (ASCT). During follow‐up, 501 (45·4%) and 129 (11·7%) patients initiated second‐ (LOT2) and third‐line therapy (LOT3), respectively. In the LOT1 setting, from 2008 to 2015, there was a decrease in the use of thalidomide‐based therapy, from 66·7% to 42·6%, and chemotherapy from, 20·2% to 5·9%, whereas use of bortezomib‐based therapy or bortezomib + thalidomide increased from 10·7% to 45·5%. Bortezomib‐based therapy and bortezomib + thalidomide were more commonly used in ASCT patients and in private clinics. In non‐ASCT and ASCT patients, median progression‐free survival (PFS) was 15·0 and 31·1 months following LOT1 and 10·9 and 9·5 months following LOT2, respectively. PFS was generally longer in patients treated with bortezomib‐based or thalidomide‐based therapy
versus
chemotherapy. These data shed light on recent trends in the management of MM in Latin America. Slower uptake of newer therapies in public clinics and poor PFS among patients with relapsed MM point to areas of unmet therapeutic need in Latin America.
Details
- Title: Subtitle
- Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016
- Creators
- Vania Tietsche de Moraes Hungria - CASADeborah M. Martínez-Baños - Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránChristian R. Peñafiel - Hospital General de MéxicoCarlos E. Miguel - Faculdade de Medicina de São José do Rio PretoJorge Vela-Ojeda - Centro Médico Nacional La RazaGuillermina Remaggi - FUNDALEU Buenos Aires ArgentinaFernando B. Duarte - Hospital Universitário Walter CantídioCarmen Cao - Instituto Nacional del CáncerMaria S. Cugliari - Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.Telma Santos - Janssen-CilagGerardo Machnicki - Janssen-CilagMariana Fernandez - Janssen-CilagMariana Grings - Janssen-CilagEric M. Ammann - Janssen (United States)Jennifer H. Lin - Janssen Scientific AffairsYen‐Wen Chen - Janssen Scientific AffairsYu‐Ning Wong - Janssen Scientific AffairsPaula Barreyro - Janssen-Cilag
- Resource Type
- Journal article
- Publication Details
- British journal of haematology, Vol.188(3), pp.383-393
- DOI
- 10.1111/bjh.16124
- PMID
- 31392724
- PMCID
- PMC7003731
- NLM abbreviation
- Br J Haematol
- ISSN
- 0007-1048
- eISSN
- 1365-2141
- Publisher
- John Wiley and Sons Inc
- Grant note
- ;
- Alternative title
- Multiple Myeloma Treatments and Outcomes in Latin America
- Language
- English
- Date published
- 08/07/2019
- Academic Unit
- Epidemiology
- Record Identifier
- 9984364421802771
Metrics
54 Record Views